Minerva Neurosciences, Inc.
$6.89
▼
-5.71%
2026-04-21 08:23:00
www.minervaneurosciences.com
NCM: NERV
Explore Minerva Neurosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$289.51 M
Current Price
$6.89
52W High / Low
$12.46 / $1.3
Stock P/E
—
Book Value
$-3.25
Dividend Yield
—
ROCE
-15.79%
ROE
352.58%
Face Value
—
EPS
$-34.67
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
7
Beta
-0.21
Debt / Equity
—
Current Ratio
36.28
Quick Ratio
36.28
Forward P/E
-11.48
Price / Sales
—
Enterprise Value
$221.1 M
EV / EBITDA
-14.64
EV / Revenue
—
Rating
Hold
Target Price
$7.25
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Traws Pharma, Inc. | $1.39 | — | $14.12 M | — | -185.49% | -10.6% | $3.27 / $0.97 | $0.64 |
| 2. | NeOnc Technologies Holdings, Inc. | $5.17 | — | $133.03 M | — | 129% | 122.08% | $12.99 / $3.2 | $-0.81 |
| 3. | Adaptive Biotechnologies Corporation | $14.58 | — | $2.23 B | — | -13.51% | -27.82% | $20.76 / $6.77 | $1.42 |
| 4. | Tango Therapeutics, Inc. | $26.39 | — | $3.8 B | — | -29.52% | -37.23% | $26.81 / $1.03 | $2.55 |
| 5. | CEL-SCI Corporation | $3.94 | — | $33.32 M | — | -107.75% | -2.12% | $13.48 / $1.98 | $1.38 |
| 6. | Damora Therapeutics, Inc. | $26.43 | — | $1.6 B | — | -87.69% | -1.64% | $29.22 / $16.5 | $-110.11 |
| 7. | Ascentage Pharma Group Internat | $25.65 | — | $18.58 B | — | -25.48% | -1.55% | $95.35 / $36.5 | $0.52 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.98 M | -2.84 M | -3.37 M | -3.9 M | -4.52 M | — |
| Net Profit | -283.67 M | -2.74 M | -3.26 M | -3.75 M | -4.27 M | — |
| EPS in Rs | -6.56 | -0.06 | -0.08 | -0.09 | -0.1 | 2.97 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -15.1 M | -21.85 M | -23.12 M | -25.23 M |
| Net Profit | -293.42 M | 1.44 M | -30.01 M | -32.11 M |
| EPS in Rs | -6.78 | 0.03 | -0.69 | -0.74 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 97.97 M | 37.14 M | 56.9 M | 55.09 M |
| Total Liabilities | 238.72 M | 62.84 M | 85.36 M | 75.11 M |
| Equity | -140.75 M | -25.69 M | -28.46 M | -20.02 M |
| Current Assets | 83.1 M | 22.27 M | 42 M | 40.16 M |
| Current Liabilities | 2.29 M | 2.84 M | 3.34 M | 1.38 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.51 M | -19.55 M | -14.78 M | -24.65 M |
| Investing CF | 0 M | 0 M | 0 M | -0.02 M |
| Financing CF | 74.45 M | 0 M | 19.6 M | -0 M |
| Free CF | -13.51 M | -19.55 M | -14.78 M | -24.66 M |
| Capex | — | — | — | -0.02 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 104.8% | 6.55% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-06-21 | 1:0.125 |